# US 2025/0049679 A1 · Formulations of eriodictyol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049679 A1
- Document ID: US20250049679A1
- Status: Published application
- Kind: A1
- Application number: 18/799,164
- Filed: 2024-08-09
- Published: 2025-02-13
- Earliest claimed: 2023-08-09
- Assignees: Debut Biotechnology, Inc.
- Applicants: Debut Biotechnology, Inc.
- Inventors: Taylor Oswald
- Web page: https://patentgrep.com/patent/US20250049679A1

## CPC

- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/062: {Oil-in-water emulsions}
- A61K 8/4973: {with oxygen as the only hetero atom}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The invention provides compositions comprising eriodictyol. The compositions of the invention may be administered topically, on the skin of the subject. The invention further provides methods of administration of compositions comprising eriodictyol for amelioration or treatment of a skin condition. The compositions of the invention may also be applied for improving the general appearance of the skin.

## Claims

### Claim 1

A composition for topical administration comprising an effective amount of eriodictyol.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition comprises an emulsion.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the emulsion is an oil/water emulsion.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition further comprises a solvent.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the solvent is a cosmetic solvent.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the solvent is selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauroyl sarcosinate, and any combinations thereof.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the solvent is dimethyl isosorbide.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the solvent is ethoxydiglycol.

### Claim 9 (depends on 6)

The composition of claim 6, wherein the solvent is isopropyl lauroyl sarcosinate.

### Claim 10 (depends on 1)

The composition of claim 1, which is stable under storage for at least two (2) years under ambient conditions.

### Claim 11 (depends on 1)

The composition of claim 1, which is stable under storage for at least one (1) year under ambient conditions.

### Claim 12 (depends on 1)

The composition of claim 1, which is stable under storage for at least six (6) months under ambient conditions.

### Claim 13 (depends on 1)

The composition of claim 1, which is stable under storage for at least three (3) months under ambient conditions.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 5% degradation when stored at 50° C. for one (1) month.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 10% degradation when stored at 40° C. for one (1) month.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 1% degradation when stored at 25° C. and/or 4° C. for one (1) month.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 10% degradation when stored at 40° C. for three (3) months.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 10% degradation when stored at 25° C. for three (3) months.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 10% degradation when stored at 25° C. for six (6) months.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the composition demonstrates less than about 5% degradation when stored at 4° C. for three (3) months.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the pH of the composition is from about 4 to about 8.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the pH of the composition is from about 4 to about 7.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the pH of the composition is from about 4 to about 6.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the pH of the composition is from about 4 to about 5.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the composition of pH is about 4.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 28 (depends on 1)

The composition of claim 1, wherein the composition of pH is about 5.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 30 (depends on 1)

The composition of claim 1, wherein the composition of pH is about 6.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 32 (depends on 1)

The composition of claim 1, wherein the composition of pH is about 7.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 34 (depends on 1)

The composition of claim 1, wherein eriodictyol is present in a concentration of about 0.0001% to about 5.0% w/w.

### Claim 35 (depends on 1)

The composition of claim 1, wherein eriodictyol is present in a concentration of about 0.0001% to about 1.0% w/w.

### Claim 36 (depends on 1)

The composition of claim 1, wherein eriodictyol is present in a concentration of about 0.001% to about 0.5% w/w.

### Claim 37 (depends on 1)

The composition of claim 1, wherein eriodictyol is present in a concentration of about 0.01% to about 0.5% w/w.

### Claim 38 (depends on 1)

The composition of claim 1, wherein eriodictyol is present in a concentration of about 0.1% to about 0.5% w/w.

### Claim 39 (depends on 1)

The composition of claim 1, wherein eriodictyol is present in a concentration of about 0.5% w/w.

### Claim 40 (depends on 1)

The composition of claim 1, wherein the composition is selected from a group consisting of: fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, hair treatment, and any combination thereof.

### Claim 41 (depends on 1)

The composition of claim 1, wherein the composition further comprises one or more excipients selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and/or pH control agent.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the preservative is an antimicrobial preservative or chelating agent.

### Claim 43 (depends on 1)

The composition of claim 1, wherein eriodictyol is encapsulated.

### Claim 44 (depends on 1)

The composition of claim 1, wherein the composition further comprises one or more excipients selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, water, glycerin, propanediol, hydrogenated ethylhexyl olivate, hydrogenated olive oil unsaponifiables, polyglycerol-6-distearate, jojoba esters, polyglyceryl-3-beeswax, cetyl alcohol, cetearyl olivate, sorbitan olivate, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, Helianthus annuus (sunflower) seed oil, caprylic/capric triglyceride, phenoxyethanol, decylene glycol, and 1,2-hexanediol.

### Claim 45 (depends on 1)

The composition of claim 1, wherein the composition is:
Concentration
Ingredient
% w/w
Water
30-90
Glycerin
0-20
Propanediol
0-10
Hydrogenated Ethylhexyl Olivate
0-2
Hydrogenated Olive Oil Unsaponifiables
0-2
Polyglyceryl-6 Distearate
0-5
Jojoba Esters
0-2.5
Polyglyceryl-3 Beeswax
0-2
Cetyl Alcohol
0-2
Cetearyl Olivate
0-5
Sorbitan Olivate
0-5
Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate
0-5
Copolymer
Helianthus Annuus (Sunflower) Seed Oil
0-10
Caprylic/Capric Triglyceride
0-10
Phenoxyethanol
0-2
Decylene Glycol
0-2
1,2-Hexanediol
0-2
Eriodictyol
0.0001-5
Dimethyl Isosorbide
0-10

### Claim 46 (depends on 1)

The composition of claim 1, wherein the composition is:
Concentration
Ingredient
% w/w
Water
76.300
Glycerin
5.000
Propanediol
2.000
Hydrogenated Ethylhexyl Olivate
0.500
Hydrogenated Olive Oil Unsaponifiables
0.500
Polyglyceryl-6 Distearate
1.419
Jojoba Esters
0.407
Polyglyceryl-3 Beeswax
0.187
Cetyl Alcohol
0.187
Cetearyl Olivate
1.000
Sorbitan Olivate
1.000
Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate
1.500
Copolymer
Helianthus Annuus (Sunflower) Seed Oil
3.000
Caprylic/Capric Triglyceride
3.000
Phenoxyethanol
0.700
Decylene Glycol
0.225
1,2-Hexanediol
0.075
Eriodictyol
0.500
Dimethyl Isosorbide
2.500

### Claim 47

A method of treating or preventing a topical condition in a subject by administration of a composition comprising an effective amount of eriodictyol.

### Claim 48 (depends on 47)

The method of claim 47, wherein the administration of the composition prevents fine lines or wrinkles on skin of the subject.

### Claim 49 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to supporting firmness and elasticity of skin of the subject.

### Claim 50 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to the prevention of skin and hair damaged by reactive oxygen species.

### Claim 51 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to protection from environment aggressors on skin.

### Claim 52 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to supporting skin elasticity.

### Claim 53 (depends on 47)

The method of claim 47, wherein the topical condition is glycation.

### Claim 54 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to increase in skin and/or hair resiliency.

### Claim 55 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to increase in elasticity of skin.

### Claim 56 (depends on 47)

The method of claim 47, wherein the administration of the composition leads to prevention of skin damage.

### Claim 57 (depends on 47)

The method of claim 47, wherein the composition is administered topically.

### Claim 58 (depends on 47)

The method of claim 47, wherein the composition comprises an emulsion.

### Claim 59 (depends on 58)

The method of claim 58, wherein the emulsion is an oil/water emulsion.

### Claim 60 (depends on 47)

The method of claim 47, wherein the composition further comprises a solvent.

### Claim 61 (depends on 60)

The method of claim 60, wherein the solvent is selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauroyl sarcosinate, and any combinations thereof.

### Claim 62 (depends on 58)

The method of claim 58, wherein the solvent is dimethyl isosorbide.

### Claim 63 (depends on 58)

The method of claim 58, wherein the solvent is ethoxydiglycol.

### Claim 64 (depends on 58)

The method of claim 58, wherein the solvent is isopropyl lauroyl sarcosinate.

### Claim 65 (depends on 47)

The method of claim 47, wherein the composition is stable under storage for at least two (2) years under ambient conditions.

### Claim 66 (depends on 47)

The method of claim 47, wherein the composition is stable under storage for at least one (1) year under ambient conditions.

### Claim 67 (depends on 47)

The method of claim 47, wherein the composition is stable under storage for at least six (6) months under ambient conditions.

### Claim 68 (depends on 47)

The method of claim 47, wherein the composition is stable under storage for at least three (3) months under ambient conditions.

### Claim 69 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 5% degradation when stored at 50° C. for one (1) month.

### Claim 70 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 71 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 10% degradation when stored at 40° C. for one (1) month.

### Claim 72 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 1% degradation when stored at 25° C. and/or 4° C. for one (1) month.

### Claim 73 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 10% degradation when stored at 40° C. for three (3) months.

### Claim 74 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 10% degradation when stored at 25° C. for three (3) months.

### Claim 75 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 10% degradation when stored at 25° C. for six (6) months.

### Claim 76 (depends on 47)

The method of claim 47, wherein the composition demonstrates less than about 5% degradation when stored at 4° C. for three (3) months.

### Claim 77 (depends on 47)

The method of claim 47, wherein the pH of the composition is from about 4 to about 8.

### Claim 78 (depends on 47)

The method of claim 47, wherein the pH of the composition is from about 4 to about 7.

### Claim 79 (depends on 47)

The method of claim 47, wherein the pH of the composition is from about 4 to about 6.

### Claim 80 (depends on 47)

The method of claim 47, wherein the pH of the composition is from about 4 to about 5.

### Claim 81 (depends on 47)

The method of claim 47, wherein the composition of pH is about 4.

### Claim 82 (depends on 81)

The method of claim 81, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 83 (depends on 47)

The method of claim 47, wherein the composition of pH is about 5.

### Claim 84 (depends on 83)

The method of claim 83, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 85 (depends on 47)

The method of claim 47, wherein the composition of pH is about 6.

### Claim 86 (depends on 85)

The method of claim 85, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 87 (depends on 47)

The method of claim 47, wherein the composition of pH is about 7.

### Claim 88 (depends on 87)

The method of claim 87, wherein the composition demonstrates less than about 10% degradation when stored at 50° C. for one (1) month.

### Claim 89 (depends on 47)

The method of claim 47, wherein eriodictyol is present in a concentration of about 0.0001% to about 5.0% w/w.

### Claim 90 (depends on 47)

The method of claim 47, wherein eriodictyol is present in a concentration of about 0.0001% to about 1.0% w/w.

### Claim 91 (depends on 47)

The method of claim 47, wherein eriodictyol is present in a concentration of about 0.001% to about 0.5% w/w.

### Claim 92 (depends on 47)

The method of claim 47, wherein eriodictyol is present in a concentration of about 0.01% to about 0.5% w/w.

### Claim 93 (depends on 47)

The method of claim 47, wherein eriodictyol is present in a concentration of about 0.1% to about 0.5% w/w.

### Claim 94 (depends on 47)

The method of claim 47, wherein eriodictyol is present in a concentration of about 0.5% w/w.

### Claim 95 (depends on 47)

The method of claim 47, wherein the composition is selected from a group consisting of: fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, hair treatment, and any combination thereof.

### Claim 96 (depends on 47)

The method of claim 47, wherein the composition further comprises one or more excipients selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and/or pH control agent.

### Claim 97 (depends on 96)

The method of claim 96, wherein the preservative is an antimicrobial preservative or chelating agent.

### Claim 98 (depends on 47)

The method of claim 47, wherein the eriodictyol is encapsulated in the composition.

### Claim 99 (depends on 47)

The method of claim 47, wherein the composition further comprises one or more excipients selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, water, glycerin, propanediol, hydrogenated ethylhexyl olivate, hydrogenated olive oil unsaponifiables, polyglycerol-6-distearate, jojoba esters, polyglyceryl-3-beeswax, cetyl alcohol, cetearyl olivate, sorbitan olivate, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, Helianthus annuus (sunflower) seed oil, caprylic/capric triglyceride, phenoxyethanol, decylene glycol, and 1,2-hexanediol.

### Claim 100 (depends on 47)

The method of claim 47, wherein the composition is:
Concentration
Ingredient
% w/w
Water
30-90
Glycerin
0-20
Propanediol
0-10
Hydrogenated Ethylhexyl Olivate
0-2
Hydrogenated Olive Oil Unsaponifiables
0-2
Polyglyceryl-6 Distearate
0-5
Jojoba Esters
0-2.5
Polyglyceryl-3 Beeswax
0-2
Cetyl Alcohol
0-2
Cetearyl Olivate
0-5
Sorbitan Olivate
0-5
Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate
0-5
Copolymer
Helianthus Annuus (Sunflower) Seed Oil
0-10
Caprylic/Capric Triglyceride
0-10
Phenoxyethanol
0-2
Decylene Glycol
0-2
1,2-Hexanediol
0-2
Eriodictyol
0.0001-5
Dimethyl Isosorbide
0-10

### Claim 101 (depends on 47)

The method of claim 47, wherein the composition is:
Concentration
Ingredient
% w/w
Water
76.300
Glycerin
5.000
Propanediol
2.000
Hydrogenated Ethylhexyl Olivate
0.500
Hydrogenated Olive Oil Unsaponifiables
0.500
Polyglyceryl-6 Distearate
1.419
Jojoba Esters
0.407
Polyglyceryl-3 Beeswax
0.187
Cetyl Alcohol
0.187
Cetearyl Olivate
1.000
Sorbitan Olivate
1.000
Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate
1.500
Copolymer
Helianthus Annuus (Sunflower) Seed Oil
3.000
Caprylic/Capric Triglyceride
3.000
Phenoxyethanol
0.700
Decylene Glycol
0.225
1,2-Hexanediol
0.075
Eriodictyol
0.500
Dimethyl Isosorbide
2.500

### Claim 102

A method of modulating expression of one or more genes by administration of a composition comprising eriodictyol, wherein at least one of the genes is related to a topical condition.

### Claim 103 (depends on 102)

The method of claim 102, wherein the one more genes are selected from a group consisting of: MMP10, THBS1, TOP2A, TFPI2, MMP1, FN1, KCTD4, ATP12A, ALDH1A3, MKI67, FST, SLC13A5, IL6, IL23A, TNF, IL24, MMP3, MMP9, and/or PPFIA4.

### Claim 104 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to down-regulation of expression and/or activity of MMP10, THBS1, TOP2A, TFPI2, MMP1, FN1, KCTD4, ATP12A, ALDH1A3, MKI67, FST, SLC13A5, IL6, IL23A, TNF, IL24, MMP3, and/or MMP9.

### Claim 105 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to up-regulation of expression and/or activity of PPFIA4.

### Claim 106 (depends on 102)

The method of claim 102, wherein the administration of the composition enhances anti-inflammatory activity.

### Claim 107 (depends on 106)

The method of claim 106, wherein the administration of the composition results in downregulation of expression and/or activity of IL6, IL23a, TNF, and/or IL24.

### Claim 108 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to anti-aging activity.

### Claim 109 (depends on 108)

The method of claim 108, wherein the administration of the composition results in downregulation of expression and/or activity of MMP10, MMP9, MMP3, and MMP1.

### Claim 110 (depends on 102)

The method of claim 102, wherein the administration of the composition enhances maintenance of skin barrier lipids.

### Claim 111 (depends on 110)

The method of claim 110, wherein the administration of the composition results in upregulation of expression and/or activity of PPFIA4.

### Claim 112 (depends on 102)

The method of claim 102, wherein the administration of the composition results in prevention of formation of scar tissue after healing of wounds.

### Claim 113 (depends on 112)

The method of claim 112, wherein the administration of the composition leads to downregulation of expression and/or activity of THBS1.

### Claim 114 (depends on 102)

The method of claim 102, wherein the composition is administered topically.

### Claim 115 (depends on 114)

The method of claim 114, wherein the topical administration is undertaken on the skin of the patient.

### Claim 116 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of matrix metallopeptidase 10 (MMP10).

### Claim 117 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about twenty-five (25) fold downregulation of the activity and/or expression of matrix metallopeptidase 10 (MMP10).

### Claim 118 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of thrombospondin 1 (THBS1).

### Claim 119 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about fifteen (15) fold downregulation of the activity and/or expression of thrombospondin 1 (THBS1).

### Claim 120 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of DNA topoisomerase II-α (TOP2A).

### Claim 121 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about fifteen (15) fold downregulation of the activity and/or expression of DNA topoisomerase II-α (TOP2A).

### Claim 122 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of tissue factor pathway inhibitor 2 (TFPI2).

### Claim 123 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about fifteen (15) fold downregulation of the activity and/or expression of tissue factor pathway inhibitor 2 (TFPI2).

### Claim 124 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of matrix metallopeptidase 1 (MMP1).

### Claim 125 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about ten (10) fold downregulation of the activity and/or expression of matrix metallopeptidase 1 (MMP1).

### Claim 126 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of fibronectin 1 (FN1).

### Claim 127 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about ten (10) fold downregulation of the activity and/or expression of fibronectin 1 (FN1).

### Claim 128 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about five (5) fold downregulation of the activity and/or expression of potassium channel tetramerization domain containing 4 (KCTD4).

### Claim 129 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about fifteen (15) fold downregulation of the activity and/or expression of potassium channel tetramerization domain containing 4 (KCTD4).

### Claim 130 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of ATPase H+/K+ transporting non-gastric α2 subunit (ATP12A).

### Claim 131 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about ten (10) fold downregulation of the activity and/or expression of ATPase H+/K+ transporting non-gastric α2 subunit (ATP12A).

### Claim 132 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of aldehyde dehydrogenase 1 family member A3 (ALDH1A3).

### Claim 133 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about ten (10) fold downregulation of the activity and/or expression of aldehyde dehydrogenase 1 family member A3 (ALDH1A3).

### Claim 134 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of marker of proliferation Ki-67 (MKI67).

### Claim 135 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about ten (10) fold downregulation of the activity and/or expression of marker of proliferation Ki-67 (MKI67).

### Claim 136 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of follistatin (FST).

### Claim 137 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about ten (10) fold downregulation of the activity and/or expression of follistatin (FST).

### Claim 138 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about five (5) fold downregulation of the activity and/or expression of solute carrier family 13 member 5 (SLC13A5).

### Claim 139 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about fifteen (15) fold downregulation of the activity and/or expression of solute carrier family 13 member 5 (SLC13A5).

### Claim 140 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about five (5) fold downregulation of the activity and/or expression of interleukin 6 (IL6).

### Claim 141 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about twenty (20) fold downregulation of the activity and/or expression of interleukin 6 (IL6).

### Claim 142 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of interleukin 23 (IL23).

### Claim 143 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about five (5) fold downregulation of the activity and/or expression of interleukin 23 (IL23).

### Claim 144 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of tumor necrosis factor (TNF).

### Claim 145 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about two hundred fifty (250) fold downregulation of the activity and/or expression of tumor necrosis factor (TNF).

### Claim 146 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of interleukin 24 (IL24).

### Claim 147 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about seventy (70) fold downregulation of the activity and/or expression of interleukin 24 (IL24).

### Claim 148 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about ten (10) fold downregulation of the activity and/or expression of matrix metallopeptidase 3 (MMP3).

### Claim 149 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about fifty (50) fold downregulation of the activity and/or expression of matrix metallopeptidase 3 (MMP3).

### Claim 150 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to at least about two (2) fold downregulation of the activity and/or expression of matrix metallopeptidase 9 (MMP9).

### Claim 151 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about eight (8) fold downregulation of the activity and/or expression of matrix metallopeptidase 9 (MMP9).

### Claim 152 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about five (5) fold upregulation of the activity and/or expression of stimulated by PTPRF interacting protein α4 (PPFIA4).

### Claim 153 (depends on 102)

The method of claim 102, wherein the administration of the composition leads to about thirty (30) fold upregulation of the activity and/or expression of PTPRF interacting protein α4 (PPFIA4).

### Claim 154 (depends on 102)

The method of claim 102, wherein the administration of the composition to a subject leads to the treatment of prevention of a topical condition of the subject.

### Claim 155 (depends on 102)

The method of claim 102, wherein the administration of composition alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) maintenance of skin barrier, (ii) anti-aging, (iii) inflammation, (iv) prevention of scar formation upon wound healing, and (v) maintenance of skin barrier lipids.